Clinical Trial: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE

U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06996080) titled 'A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE' on May 21.

Brief Summary: A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Macular Edema Secondary to Inflammation

Intervention: DRUG: KSI-101

Intravitreal injection

OTHER: Sham Comparator

Sham injections

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kodiak Sciences Inc

Published by HT Digital Content Servic...